# US 2026/0184813 A1 · VHH POLYPEPTIDES THAT BIND TO LIGHT CHAIN (LC) PROTEASES OF BOTULINUM NEUROTOXINS (BoNTs) AND METHODS OF USE THEREOF

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0184813 A1
- Document ID: US20260184813A1
- Status: Published application
- Kind: A1
- Application number: 17/980,791
- Filed: 2022-11-04
- Published: 2026-07-02
- Earliest claimed: 2021-11-04
- Assignees: Trustees of Tufts College
- Applicants: Trustees of Tufts College
- Inventors: Charles B. SHOEMAKER
- Web page: https://patentgrep.com/patent/US20260184813A1

## CPC

- C07K 16/40: against enzymes
- A61K 47/6893: {clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M}
- A61P 39/02: Antidotes
- C07K 16/1282: Clostridium (G)
- G01N 33/573: for enzymes or isoenzymes
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2333/952: derived from bacteria
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Products, pharmaceutical compositions, methods of use, and kits are provided for treating a patient suffering from botulinum neurotoxin intoxication. Featured are single-domain variable heavy-chain (VHH) polypeptides (antibodies) that target and neutralize the light chain (LC) protease domains of botulinum neurotoxin (BoNT), i.e., BoNT LC/A and BoNT LC/B, and that advantageously provide late and post-exposure therapy for botulism patients. The LC/A toxin-binding and LC/B toxin-binding VHH polypeptides, which can be recombinantly produced, specifically bind to the LCs of the botulinum neurotoxins to inhibit toxin activity and treat intoxication.

## Claims

### Claim 1

A VHH polypeptide that specifically binds to a light chain (LC) protease domain of Botulinum neurotoxin (BoNT) serotype A (LC/A) or a LC/A-binding portion thereof, or to a light chain (LC) protease domain of Botulinum neurotoxin (BoNT) serotype B (LC/B), or a LC/B-binding portion thereof,
wherein the VHH polypeptide that binds to the LC/A neurotoxin comprises complementarity determining regions (CDRs), CDR1, CDR2 and CDR3, comprising amino acid sequences selected from:
CDR1: SGFTLDDYAIGWF as set forth in SEQ ID NO: 38; CDR2: SRSGDTYYP as set forth in SEQ ID NO: 39; and CDR3: DFPPVRPMCIQAAPKKR as set forth in SEQ ID NO: 40;
CDR1: SGADFSFYAMGWY as set forth in SEQ ID NO: 41; CDR2: NLNGVISYG as set forth in SEQ ID NO: 42; and CDR3: MRLYTRGSVRHPESW as set forth in SEQ ID NO: 43;
CDR1: TGRTLDYYALGWF as set forth in SEQ ID NO: 44; CDR2: NWLGGSTYYA as set forth in SEQ ID NO: 45; and CDR3: DFSIAYSGTYPPAYAEYDYDYW as set forth in SEQ ID NO: 46;
CDR1: SGSPLSIWVMGWY as set forth in SEQ ID NO: 47; CDR2: NLNGITSYG as set forth in SEQ ID NO: 48; and CDR3: EPLGPRGKKSGKEYW as set forth in SEQ ID NO: 49;
CDR1: TSENVFGIYGMAW as set forth in SEQ ID NO: 50; CDR2: ITSRGTAHYH as set forth in SEQ ID NO: 51; and CDR3: GPYW as set forth in SEQ ID NO: 52;
CDR1: SGFTFNRYVIRWY as set forth in SEQ ID NO: 53; CDR2: SRSGDSGRYV as set forth in SEQ ID NO: 54; and CDR3: LNLEDMEYW as set forth in SEQ ID NO: 55;
CDR1: SGNIFSIYYMGWY as set forth in SEQ ID NO: 56; CDR2: NSNGITNYG as set forth in SEQ ID NO: 57; and CDR3: GKLRRTTGWGLDDYW as set forth in SEQ ID NO: 58;
CDR1: SGFTLDEYAIGWF as set forth in SEQ ID NO: 59; CDR2: SSSASISYA as set forth in SEQ ID NO: 60; and CDR3: AFLACGPVAGWGTEYDYW as set forth in SEQ ID NO: 61;
CDR1: STTISDFYSMGWF as set forth in SEQ ID NO: 62; CDR2: RRGGDTKSG as set forth in SEQ ID NO: 63; and CDR3: NLQKSSDELGPYYW as set forth in SEQ ID NO: 64;
CDR1: SLLTLEYYAIGWF as set forth in SEQ ID NO: 65; CDR2: GSSGGSTVYI as set forth in SEQ ID NO: 66; and CDR3: DDLRCGRGWSSYFRGSW as set forth in SEQ ID NO: 67;
CDR1: SESVFEMYTVAWY as set forth in SEQ ID NO: 68; CDR2: TDEGRTNYA as set forth in SEQ ID NO: 69; and CDR3: EHDLGYYDYW as set forth in SEQ ID NO: 70;
CDR1: SGLTLDYYAIGWF as set forth in SEQ ID NO: 71; CDR2: SSGSSMSIHA as set forth in SEQ ID NO: 72; and CDR3: DDFTCGSRWSDWAHTFGFW as set forth in SEQ ID NO: 73; or
CDR1: SGGIFSTYIMGWY as set forth in SEQ ID NO: 74; CDR2: SNHTTDYA as set forth in SEQ ID NO: 75; and CDR3: DWMVGAWTAGDYGVDYW as set forth in SEQ ID NO: 76; and
wherein the VHH polypeptide that binds to the LC/B neurotoxin comprises complementarity determining regions (CDRs), CDR1, CDR2 and CDR3, comprising amino acid sequences selected from:
CDR1: SGLSFNWYDVG as set forth in SEQ ID NO: 77; CDR2: SRSSGGGSTY as set forth in SEQ ID NO: 78; and CDR3: AADWTGRAGFSVGYYRPDEYDY as set forth in SEQ ID NO: 79;
CDR1: SGFTLDSYAIG as set forth in SEQ ID NO: 80; CDR2: CMSSGDGSTY as set forth in SEQ ID NO: 81; and CDR3: AADGFDYCSAYVPGRGMNY as set forth in SEQ ID NO: 82;
CDR1: SGFTLDNYAVG as set forth in SEQ ID NO: 83; CDR2: CISSSDDNTD as set forth in SEQ ID NO: 84; and CDR3: AAESPTFGFSCTVATDPYDY as set forth in SEQ ID NO: 85;
CDR1: SGFTLDGYAAG as set forth in SEQ ID NO: 86; CDR2: WISSTDGSTY as set forth in SEQ ID NO: 87; and CDR3: TAGLGLDVSDYVYDY as set forth in SEQ ID NO: 88;
CDR1: SGFTLDYYGIG as set forth in SEQ ID NO: 89; CDR2: CITSGGLTN as set forth in SEQ ID NO: 90; and CDR3: AIDRVGVCAMEDFGS as set forth in SEQ ID NO: 91;
CDR1: SGRTFNYYAMA as set forth in SEQ ID NO: 92; CDR2: FINWSGDSTY as set forth in SEQ ID NO: 93; and CDR3: AAEFGTFSYLQGDDYSY as set forth in SEQ ID NO: 94;
CDR1: SGRSFSSYRMG as set forth in SEQ ID NO: 95; CDR2: GISWSGSSTW as set forth in SEQ ID NO: 96; and CDR3: AADGLGTDWSDAIWDY as set forth in SEQ ID NO: 97;
CDR1: SGRMFNEYRMG as set forth in SEQ ID NO: 98; CDR2: AINWGAQIPY as set forth in SEQ ID NO: 99; and CDR3: AADWGYGSSPHQDKEYDY as set forth in SEQ ID NO: 100;
CDR1: SGRTFSDYAMG as set forth in SEQ ID NO: 101; CDR2: AVDWSGSSRL as set forth in SEQ ID NO: 102; and CDR3: AAARNRWSSEISSYDY as set forth in SEQ ID NO: 103;
CDR1: SGRTFRRNTMG as set forth in SEQ ID NO: 104; CDR2: AISWSGDRTY as set forth in SEQ ID NO: 105; and CDR3: AADGTASVFNSYASADRNKYNY as set forth in SEQ ID NO: 106;
CDR1: SIRTFSTSTTA as set forth in SEQ ID NO: 107; CDR2: RISGSDPVTY as set forth in SEQ ID NO: 108; and CDR3: ATVRIKGGSEFSYHY as set forth in SEQ ID NO: 109;
CDR1: SESTFSINAIG as set forth in SEQ ID NO: 110; CDR2: HISTSGRTR as set forth in SEQ ID NO: 111; and CDR3: NAEGYSTWPEDRYLEL as set forth in SEQ ID NO: 112;
CDR1: SGRTFSSYRMGMG as set forth in SEQ ID NO: 113; CDR2: TVNWSGGTTY as set forth in SEQ ID NO: 114; and CDR3: AAGRGSESYTSSRYNY as set forth in SEQ ID NO: 115; or
CDR1: SGFTLDDYAIG as set forth in SEQ ID NO: 116; CDR2: CISIRDGRTH as set forth in SEQ ID NO: 117; and CDR3: AAGQRSMAYVCSNRFGS as set forth in SEQ ID NO: 118.

### Claim 2 (depends on 1)

The polypeptide of claim 1, further comprising a framework region.

### Claim 3 (depends on 1)

The polypeptide of claim 1, wherein the VHH polypeptide that binds to the LC/A neurotoxin comprises complementarity determining regions (CDRs), CDR1, CDR2 and CDR3, comprising amino acid sequences:
CDR1: SGADFSFYAMGWY as set forth in SEQ ID NO: 41; CDR2: NLNGVISYG as set forth in SEQ ID NO: 42; and CDR3: MRLYTRGSVRHPESW as set forth in SEQ ID NO: 43;
CDR1: TGRTLDYYALGWF as set forth in SEQ ID NO: 44; CDR2: NWLGGSTYYA as set forth in SEQ ID NO: 45; and CDR3: DFSIAYSGTYPPAYAEYDYDYW as set forth in SEQ ID NO: 46;
CDR1: SGFTFNRYVIRWY as set forth in SEQ ID NO: 53; CDR2: SRSGDSGRYV as set forth in SEQ ID NO: 54; and CDR3: LNLEDMEYW as set forth in SEQ ID NO: 55;
CDR1: SGNIFSIYYMGWY as set forth in SEQ ID NO: 56; CDR2: NSNGITNYG as set forth in SEQ ID NO: 57; and CDR3: GKLRRTTGWGLDDYW as set forth in SEQ ID NO: 58;
CDR1: SGFTLDEYAIGWF as set forth in SEQ ID NO: 59; CDR2: SSSASISYA as set forth in SEQ ID NO: 60; and CDR3: AFLACGPVAGWGTEYDYW as set forth in SEQ ID NO: 61; or
CDR1: STTISDFYSMGWF as set forth in SEQ ID NO: 62; CDR2: RRGGDTKSG as set forth in SEQ ID NO: 63; and CDR3: NLQKSSDELGPYYW as set forth in SEQ ID NO: 64; or
wherein the VHH polypeptide that binds to the LC/B neurotoxin comprises complementarity determining regions (CDRs), CDR1, CDR2 and CDR3, comprising amino acid sequences:
CDR1: SGRTFRRNTMG as set forth in SEQ ID NO: 104; CDR2: AISWSGDRTY as set forth in SEQ ID NO: 105; and CDR3: AADGTASVFNSYASADRNKYNY as set forth in SEQ ID NO: 106.

### Claim 4

A VHH polypeptide that specifically binds to a light chain (LC) protease domain of Botulinum neurotoxin (BoNT) serotype A (LC/A) or a LC/A-binding portion thereof, or to a light chain (LC) protease domain of Botulinum neurotoxin (BoNT) serotype B (LC/B) or a LC/B-binding portion thereof, wherein the VHH polypeptide that binds to the LC/A toxin comprises an amino acid sequence having at least 85% sequence identity to an amino acid sequence of an LC/A-binding polypeptide selected from the group consisting of JPU-A1 as set forth in SEQ ID NO: 7; JPU-A5 as set forth in SEQ ID NO: 8; JPU-A11 as set forth in SEQ ID NO: 9; JPU-B5 as set forth in SEQ ID NO: 10; JPU-B9 as set forth in SEQ ID NO: 11; JPU-C1 as set forth in SEQ ID NO: 12; JPU-C10 as set forth in SEQ ID NO: 13; JPU-D12 as set forth in SEQ ID NO: 14; JPU-G3 as set forth in SEQ ID NO: 15; JPU-G7 as set forth in SEQ ID NO: 16; JPU-G11 as set forth in SEQ ID NO: 17; JPU-G12 as set forth in SEQ ID NO: 18; and JPU-H7 as set forth in SEQ ID NO: 19; or wherein the VHH polypeptide that binds to the LC/B toxin comprises an amino acid sequence having at least 85% sequence identity to an amino acid sequence of an LC/B toxin binding polypeptide selected from the group consisting of JND-A12 as set forth in SEQ ID NO: 24; JND-B4 as set forth in SEQ ID NO: 25; JND-C7 as set forth in SEQ ID NO: 26; JND-E4 as set forth in SEQ ID NO: 27; JND-E5 as set forth in SEQ ID NO: 28; JND-E9 as set forth in SEQ ID NO: 29; JND-F3 as set forth in SEQ ID NO: 30; JSG-B8 as set forth in SEQ ID NO: 31; JSG-B10 as set forth in SEQ ID NO: 32; JSG-C1 as set forth in SEQ ID NO: 33; JSG-F6 as set forth in SEQ ID NO: 34; JSG-G1 as set forth in SEQ ID NO: 35; JSG-G10 as set forth in SEQ ID NO: 36; and JSG-G11 as set forth in SEQ ID NO: 37.

### Claim 5 (depends on 4)

The VHH polypeptide of claim 4, wherein the VHH polypeptide that binds to the LC/A toxin comprises an amino acid sequence having at least 85% sequence identity to an amino acid sequence of an LC/A toxin-binding polypeptide selected from the group consisting of JPU-A5 as set forth in SEQ ID NO: 8, JPU-A11 as set forth in SEQ ID NO: 9, JPU-C1 as set forth in SEQ ID NO: 12, JPU-C10 as set forth in SEQ ID NO: 13, JPU-D12 as set forth in SEQ ID NO: 14, or JPU-G3 as set forth in SEQ ID NO: 15; or wherein the VHH polypeptide that binds to the LC/B toxin comprises an amino acid sequence having at least 85% sequence identity to the amino acid sequence of LC/B toxin-binding VHH polypeptide JSG-C1 as set forth in SEQ ID NO: 33

### Claim 6

A VHH polypeptide that specifically binds to a light chain (LC) protease domain of Botulinum neurotoxin (BoNT) serotype A (LC/A) or a LC/A-binding portion thereof, or to a light chain (LC) protease domain of Botulinum neurotoxin (BoNT) serotype B (LC/B) or a LC/B-binding portion thereof, wherein the VHH polypeptide that binds to LC/A comprises or consists of JPU-A1 as set forth in SEQ ID NO: 7; JPU-A5 as set forth in SEQ ID NO: 8; JPU-A11 as set forth in SEQ ID NO: 9; JPU-B5 as set forth in SEQ ID NO: 10; JPU-B9 as set forth in SEQ ID NO: 11; JPU-C1 as set forth in SEQ ID NO: 12; JPU-C10 as set forth in SEQ ID NO: 13; JPU-D12 as set forth in SEQ ID NO: 14; JPU-G3 as set forth in SEQ ID NO: 15; JPU-G7 as set forth in SEQ ID NO: 16; JPU-G11 as set forth in SEQ ID NO: 17; JPU-G12 as set forth in SEQ ID NO: 18; and JPU-H7 as set forth in SEQ ID NO: 19; or wherein the VHH polypeptide that binds to LC/B comprises or consists of JND-A12 as set forth in SEQ ID NO: 24; JND-B4 as set forth in SEQ ID NO: 25; JND-C7 as set forth in SEQ ID NO: 26; JND-E4 as set forth in SEQ ID NO: 27; JND-E5 as set forth in SEQ ID NO: 28; JND-E9 as set forth in SEQ ID NO: 29; JND-F3 as set forth in SEQ ID NO: 30; JSG-B8 as set forth in SEQ ID NO: 31; JSG-B10 as set forth in SEQ ID NO: 32; JSG-C1 as set forth in SEQ ID NO: 33; JSG-F6 as set forth in SEQ ID NO: 34; JSG-G1 as set forth in SEQ ID NO: 35; JSG-G10 as set forth in SEQ ID NO: 36; and JSG-G11 as set forth in SEQ ID NO: 37.

### Claim 7 (depends on 6)

The VHH polypeptide of claim 6, wherein the LC/A-binding VHH polypeptide comprises or consists of JPU-A5 as set forth in SEQ ID NO: 8, JPU-A11 as set forth in SEQ ID NO: 9, JPU-C1 as set forth in SEQ ID NO: 12, JPU-C10 as set forth in SEQ ID NO: 13, JPU-D12 as set forth in SEQ ID NO: 14, or JPU-G3 as set forth in SEQ ID NO: 15; or wherein the LC/B-binding VHH polypeptide comprises or consists of JSG-C1 as set forth in SEQ ID NO: 33.

### Claim 8 (depends on 1)

The polypeptide of claim 1, wherein the polypeptide inhibits and/or neutralizes BoNT/A LC/A protease function or activity or inhibits and/or neutralizes BoNT/B LC/B protease function or activity.

### Claim 9 (depends on 4)

The polypeptide of claim 4, wherein conservative amino acid substitutions in the polypeptide comprise the at least 85% amino acid sequence identity.

### Claim 10 (depends on 1)

The polypeptide of claim 1, which is a camelid-derived single domain anti-LC/A toxin or LC/B toxin VHH antibody.

### Claim 11 (depends on 1)

The polypeptide of claim 1, comprising one or more epitope tag sequences specifically bindable by an anti-epitope tag antibody or binding portion thereof.

### Claim 12 (depends on 11)

The polypeptide of claim 11, wherein the one or more epitope tag sequences comprises at least one of DELGPRLMGK as set forth in SEQ ID NO: 119 or GAPVPYPDPLEPR as set forth in SEQ ID NO: 120.

### Claim 13 (depends on 1)

The polypeptide of claim 1, in the form of a dimer or multimer.

### Claim 14 (depends on 13)

The polypeptide of claim 13, comprising two or more anti-LC/A toxin and/or anti-LC/B toxin VHH polypeptides, or LC/A-toxin or LC/B-toxin binding portions thereof, joined with one or more linker peptides.

### Claim 15 (depends on 14)

The polypeptide of claim 14, wherein the one or more linker peptides is selected from GGGGS as set forth in SEQ ID NO: 121; GGGGSGGGGSGGGGS as set forth in SEQ ID NO: 122, or a functional portion thereof, EPKTPKPQGGGGSGGGGSGGGGSQGVQSQVQLVE as set forth in SEQ ID NO: 123; EPKTPKPQ as set forth in SEQ ID NO: 124; or a combination thereof.

### Claim 16 (depends on 14)

The polypeptide of claim 14, wherein the polypeptide is dimeric and comprises (i) two anti-LC/A-toxin VHH polypeptides, same or different; (ii) two anti-LC/B-toxin VHH polypeptides, same or different; or (iii) a combination of an anti-LC/A-toxin VHH polypeptide and an anti-LC/B-toxin VHH polypeptide.

### Claim 17 (depends on 13)

The polypeptide of claim 13, wherein the polypeptide is multimeric and comprises (i) at least three anti-LC/A toxin VHH polypeptides, same or different; (ii) at least three anti-LC/B toxin VHH polypeptides, same or different; or (iii) a combination of at least three anti-LC/A-toxin VHH polypeptides and anti-LC/B-toxin VHH polypeptides.

### Claim 18 (depends on 1)

An isolated polynucleotide encoding the polypeptide of claim 1.

### Claim 19 (depends on 18)

A vector comprising the isolated polynucleotide of claim 18; optionally, wherein the vector is a viral or a non-viral expression vector.

### Claim 20 (depends on 19)

A host cell comprising the vector of claim 19.

### Claim 21 (depends on 1)

A pharmaceutical composition comprising an effective amount of the polypeptide of claim 1 and a pharmaceutically acceptable excipient, carrier, or diluent.

### Claim 22 (depends on 4)

A pharmaceutical composition comprising an effective amount of the polypeptide of claim 4 and a pharmaceutically acceptable excipient, carrier, or diluent.

### Claim 23 (depends on 1)

A method of treating botulism or intoxication associated with activity of Botulinum LC/A and/or LC/B neurotoxins, and/or the symptoms thereof, the method comprising administering to a subject in need thereof an effective amount of the polypeptide of claim 1, or a polynucleotide encoding the polypeptide, or a pharmaceutical composition thereof, thereby treating botulism or infection by Botulinum microorganisms of serotype A and/or B, and/or the symptoms thereof in the subject.

### Claim 24 (depends on 4)

A method of treating botulism or intoxication associated with activity of Botulinum LC/A and/or LC/B neurotoxins, and/or the symptoms thereof, the method comprising administering to a subject in need thereof an effective amount of the polypeptide of claim 4, or a polynucleotide encoding the polypeptide, or a pharmaceutical composition thereof, thereby treating botulism or infection by Botulinum microorganisms of serotype A and/or B, and/or the symptoms thereof in the subject.

### Claim 25 (depends on 1)

A method of reducing the severity of botulism or intoxication associated with activity of Botulinum LC/A and/or LC/B neurotoxins, and/or the symptoms thereof, in a subject who has, who is susceptible to, or who is at risk of having, botulism or intoxication by the Botulinum microorganisms, the method comprising administering to a subject in need thereof an effective amount of the polypeptide of claim 1, or a polynucleotide encoding the polypeptide, or a pharmaceutical composition thereof, thereby reducing the severity of botulism or intoxication by the LC/A and/or LC/B neurotoxin-producing Botulinum microorganisms and/or the symptoms thereof in the subject.

### Claim 26 (depends on 4)

A method of reducing the severity of botulism or intoxication associated with activity of Botulinum LC/A and/or LC/B neurotoxins, and/or the symptoms thereof in a subject who has, who is susceptible to, or who is at risk of having, botulism or intoxication by the Botulinum neurotoxins, the method comprising administering to a subject in need thereof an effective amount of the polypeptide of claim 4, or a polynucleotide encoding the polypeptide, or a pharmaceutical composition thereof, thereby reducing the severity of botulism or intoxication by the LC/A and/or LC/B neurotoxin-producing Botulinum microorganisms and/or the symptoms thereof in the subject.

### Claim 27

The method of 23, further comprising administering to the subject an anti-epitope tag antibody that specifically binds to an epitope tag, if present, and facilitates clearance of a complex of LC/A and/or LC/B bound to the anti-LC/A and/or anti-LC/B VHH polypeptide from the subject.

### Claim 28

The method of 24, further comprising administering to the subject an anti-epitope tag antibody that specifically binds to an epitope tag, if present, and facilitates clearance of a complex of LC/A and/or LC/B bound to the anti-LC/A and/or anti-LC/B VHH polypeptide from the subject.

### Claim 29 (depends on 23)

The method of claim 23, wherein the VHH polypeptide provides post-exposure or late post-exposure therapeutic treatment for patients suffering from botulism.

### Claim 30 (depends on 24)

The method of claim 24, wherein the VHH polypeptide provides post-exposure or late post-exposure therapeutic treatment for patients suffering from botulism.

### Claim 31 (depends on 1)

A kit comprising the polypeptide of claim 1, or a pharmaceutical composition thereof, for treating or protecting against disease or intoxication and/or the symptoms thereof caused by Botulinum LC/A toxin protease and/or Botulinum LC/B toxin protease; and optionally comprising instructions for use.

### Claim 32 (depends on 1)

A method of detecting botulinum protease LC/A and/or LC/B in a sample, the method comprising contacting the sample with one or more VHH polypeptides of claim 1 under conditions for detecting the binding of the VHH polypeptide to the LC/A and/or the LC/B in the sample.
